Beranda › Sklerosis Multipel
Uji klinis Sklerosis Multipel yang merekrut di AS
131 studi untuk Sklerosis Multipel merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- New York City, NY17 studi
- Chicago, IL15 studi
- Boston, MA14 studi
- Washington, DC13 studi
- Cleveland, OH9 studi
- Kansas City, KS8 studi
- St. Louis, MO8 studi
- Birmingham, AL8 studi
- San Francisco, CA8 studi
- Aurora, CO7 studi
- Baltimore, MD7 studi
- Columbus, OH7 studi
- Houston, TX6 studi
- Seattle, WA6 studi
- Milwaukee, WI6 studi
- Dallas, TX6 studi
- Farmington Hills, MI6 studi
- Austin, TX5 studi
- San Diego, CA5 studi
- Atlanta, GA5 studi
- Tampa, FL5 studi
- Durham, NC4 studi
- Ann Arbor, MI4 studi
- Naples, FL4 studi
- Knoxville, TN4 studi
- Scottsdale, AZ4 studi
- Orlando, FL4 studi
- Champaign, IL4 studi
- Brockton, MA4 studi
- Miami, FL4 studi
- New Haven, CT4 studi
- Cincinnati, OH3 studi
- Rochester, MN3 studi
- Gainesville, FL3 studi
- Newark, NJ3 studi
- Phoenix, AZ3 studi
- Sandy Springs, GA3 studi
- El Paso, TX3 studi
- Burbank, CA3 studi
- Raleigh, NC3 studi
Berdasarkan negara bagian
- Alabama8 studi
- Arizona6 studi
- California24 studi
- Colorado11 studi
- Connecticut6 studi
- Distrik Columbia4 studi
- Florida14 studi
- Georgia7 studi
- Hawaii3 studi
- Illinois19 studi
- Kansas9 studi
- Kentucky3 studi
- Maryland17 studi
- Massachusetts18 studi
- Michigan10 studi
- Minnesota4 studi
- Missouri8 studi
- Nebraska3 studi
- New Jersey11 studi
- New York19 studi
- North Carolina8 studi
- Ohio14 studi
- Oklahoma3 studi
- Pennsylvania7 studi
- Tennessee6 studi
- Texas17 studi
- Utah3 studi
- Virginia3 studi
- Washington10 studi
- Wisconsin7 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Menerima pesertaFase 4
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07609719Vancomycin Study in Multiple Sclerosis (MS)
Menerima pesertaFase 1
Usia 18 hingga 50 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05539729Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis
Menerima peserta
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07475377A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07840326A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06433752Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Menerima pesertaStudi observasionalSukarelawan sehat diterima
1 Month – 99 Years · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT00794352Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Menerima pesertaFase 1/2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07477639A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Menerima pesertaStudi observasional
Usia 15 hingga 50 · Wanita · Diperbarui 21 Sep 2026 · NCT06433765Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07606742Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT00001248Clinical Applications of Advanced Ophthalmic Imaging
Menerima pesertaSukarelawan sehat diterima
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT03135327Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Menerima pesertaFase 2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT02784210Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Menerima pesertaFase 3
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07325292Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Menerima peserta
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05958381RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07002034Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Menerima pesertaFase 3
Usia 10 hingga 17 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06408259A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06680037Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06999434Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 120 · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT01730131Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Menerima peserta
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07132775Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Menerima pesertaFase 1/2
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT03109288Identifying and Characterizing Preclinical MS
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Agu 2026 · NCT05787795An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Menerima pesertaFase 1
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07224373Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.